References
- Kessler RC, Birnbaum HG, Shahly V, et al. Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey Initiative. Depress Anxiety 2010;27:351-64
- Hildrum B, Romild U, Holmen J. Anxiety and depression lowers blood pressure: 22-year follow-up of the population based HUNT study, Norway. BMC Public Health 2011;11:601
- Vilhelmsson A. Depression and antidepressants: a Nordic perspective. Front Public Health 2013;1:30
- Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med 2011;41:1165-74
- Lam RW, Iverson GL, Evans VC, et al. The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder. J Affect Disord 2016;203:55-61
- McIntyre RS, Xiao HX, Syeda K, et al. The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder. CNS Drugs 2015;29:577-89
- McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication [published correction appears in J Clin Psychopharmacol 2013;33:765]. J Clin Psychopharmacol 2011;31:180-6
- Greer TL, Kurian BT, Trivedi MH. Defining and measuring functional recovery from depression. CNS Drugs 2010;24:267-84
- Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther 2015;145:43-57
- McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014;17:1557-67
- Mahableshwarkar AR, Zajecka J, Jacobson W, et al. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 2016;41:2961
- Christensen MC, Loft H, McIntyre RS. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: a novel dual outcome measure in depressive disorders. J Affect Disord 2017;227:787-94
- Harvey PD, Jacobson W, Zhong W, et al. Determination of a clinically important difference and definition of a responder threshold for the UCSD Performance-Based Skills Assessment (UPSA) in patients with major depressive disorder. J Affect Disord 2017;213:105-11
- Olsen CK, McIntyre R, Lophaven S, et al. Clinical relevance of subjective cognitive assessment in patients with major depressive disorder. Paper presented at the American Psychiatric Association 2015 Annual Meeting; May 2015; Toronto, ON, Canada
- Choi SE, Brignone M, Cho SJ, et al. Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea. Expert Rev Pharmacoecon Outcomes Res 2016;16:629-38
- Soini E, Hallinen T, Brignone M, et al. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert Rev Pharmacoecon Outcomes Res 2017;17:293-302
- Statens legemiddelverk [Norwegian Medicines Agency medicine database]. Available at: https://www.legemiddelsok.no/. [Last accessed 30 March 2017]
- Ramsberg J, Asseburg C, Henriksson M. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One 2012;7:e42003
- Gelenberg AJ, Freeman MP, Markowitz JC, et al. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington, VA: American Psychiatric Association; 2010. Available at: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. [Last accessed 20 July 2017]
- Mars B, Heron J, Gunnell D, et al. Prevalence and patterns of antidepressant switching amongst primary care patients in the UK. J Psychopharmacol 2017;31:553-60
- Citrome L. Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord 2016;196:225-33
- McIntyre RS, Lee Y, Mansur RB. Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectr 2015;20(Suppl 1):17-31